ThromboGenics (THR)

Business description

ThromboGenics is a Belgian biopharmaceutical company focused on developing and commercialising the eye drug ocriplasmin; EU (via Alcon) and US launches are due in Q113. Antibody candidates targeting cardiovascular disorders and cancer are in mid-stage clinical trials.

Clearing blurred vision

QuickView | Pharmaceutical & healthcare | 09/09/2013

ThromboGenics’ share price has tumbled c 25% following commentary at the H113 financial results that US sales of Jetrea are not expected to grow in H2. While this is clearly disappointing given the early stage of launch, the current share price is now at levels previously seen more than a year ago, before Jetrea had even been approved. Sales progression could take time, but any uptick or updated positive commentary from management could provide upside from current levels.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.